Ocrelizumab: its efficacy and safety in multiple sclerosis

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Ocrelizumab is a humanized monoclonal antibody targeting CD20 on B cells.
• It is the first approved therapy for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).
• Regulatory approval has been granted by the US Food and Drug Administration and European Medicines Agency.

Purpose of the Study:

• To review the efficacy and safety of ocrelizumab in multiple sclerosis (MS).
• To consolidate findings from key clinical trials and post-marketing surveillance.

Main Methods:

• Literature review of studies presented at ECTRIMS 2017 and active ClinicalTrials.
• Inclusion of randomized controlled trials, extension studies, and regulatory safety monitoring data.
• Evaluation focused on ocrelizumab's impact on MS clinical and radiological outcomes.

Main Results:

• Ocrelizumab demonstrated significant slowing of disability progression in PPMS at 12 and 24 weeks.
• Effective control of clinical and radiological activity was observed in RRMS patients.
• The drug is approved and indicated for both major MS phenotypes.

Conclusions:

• Ocrelizumab is the first therapy to significantly slow disability progression in PPMS.
• It offers efficacy in managing both RRMS and PPMS.
• Current safety data align with clinical trial findings, with no new safety concerns identified.